Scientist with 14 years lab experience including 3 years in the pharmaceutical industry. Expertise in drug development, mass spectrometry, pharmacokinetics/pharmacodynamics, molecular cloning and recombinant protein production.

University of California--San Diego

Biochemistry and Cell Biology BASc '14, University of California--San Diego

University of California--Davis

Pharmacology & Toxicology PhD '24, University of California--Davis

Pharmacology | Cancer Research | Art | Music

Pharmacology

Molecular Biology

Artificial Intelligence

Safety Research

Cancer Research

Pulmonary And Respiratory Medicine

Applied Psychology

Biomaterials

Cognitive Neuroscience

Cellular And Molecular Neuroscience

Oncology

Biochemistry

Biological Psychiatry

Clinical Psychology

Rheumatology

Finance

Physiology

Organic Chemistry

Dermatology

Spectroscopy

Materials Chemistry

Immunology

Pharmaceutical Science

Surgery

Pathology And Forensic Medicine

Focus areas: cell biology, stem cell biology, cardiac biology,  cell/tissue/organ engineering, organoids, in vitro models, drug discovery, cell reprogramming, cell and gene therapy, biotechnology, biomaterials, microfluidics & microtechnologies, longevity biotechnology, experimental design.

Open & decentralized science | Lab automation | Bioengineering

Biology

Dr. Nelson is an Associate Professor with tenure in the Department of Biochemistry, Biophysics, and Molecular Biology at Iowa State University.  His lab investigates the molecular mechanisms of DNA replication and repair with a focus on infectious organisms.

Enzymology of DNA Replication and Repair

I will offer 1,000 RSC to the best answer to this question, and an additional 250 RSC for up to 2 other answers which are useful for informing my experimental design. I'm going to be using 3rd generation lentiviral transduction to take a cell line which has a knockout for a protein and create clones which express wild-type and various mutants of this particular protein. The vector I've cloned my gene of interest into has GFP, so my plan is to transfect HEK293T cells, harvest viral particles, transduce my target cells, use FACS to sort GFP-positive cells, do a limiting dilution, and then grow up clones. I'm thinking of using this protocol (https://rnai.genmed.sinica.edu.tw/file/protocol/43EstimationLentivirusTiterGFPV1.pdf)Is it okay if I never measure the actual number of viral particles? I just want to transduce in such a way that each cell gets infected once, so I'm thinking of transducing cells with a variety of dilutions of my viral particles, and go with whatever dilution of the particles gives me less than ~20% of cells fluorescing, which should be each of those cells infected roughly once. Am I missing something here? Why would you ever need to measure MOI? To me it seems superfluous to measure the number of actual viral particles when the number you need is also variable depending on cell type. Never done this before so I'd appreciate any insight! 

Do you actually NEED to calculate multiplicity of infection (MOI) when establishing a stable cell line using lentiviral transduction?  

Do you actually NEED to calculate multiplicity of infection (MOI) when establishing a stable cell line using lentiviral transduction?

Scan to connect with one of our mobile apps

Coinbase Wallet app

Coinbase app

Or try the Coinbase Wallet browser extension